Insightec seeks Parkinson ’ s indication in Japan for Exablate Neuro

Insightec said this week it submitted an application for pre-market approval to the Japanese Pharmaceuticals and Medical Devices Agency seeking an indication for its Exablate Neuro to treat advanced Parkinson’s Disease in patients suffering from mobility, rigidity or dyskinesia. The Israel-based company’s Exablate Neuro device uses high-intensity, focused ultrasound to thermally ablate targeted tissue, guided by continuous magnetic resonance imaging; the procedure can be performed non-invasively through an intact skull. “Insightec is committed to supporting research that extends the applications and potential of focused ultrasound, to improve the lives of people living with Parkinson’s disease with a much less invasive approach than conventional surgery,” CEO Dr. Maurice Ferré said in a press release. The Exablate Neuro is currently approved in Japan to treat medication-refractory essential tumor, with a total of seven medical institutions in the country performing procedures with the device on a routine basis, Insightec said. In January, Insightec said that  it closed a $150 million Series E private equity round of financing with plans to use funds to support marketing, commercialization and further development of its Exablate Neuro platform. The post Insightec seeks Parkinson’s indication in Japan for Exablate Neuro appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Neurological Regulatory/Compliance Ultrasound INSIGHTEC Source Type: news

Related Links:

Parkinson's disease is neurodegenerative disorder with an initial robust response to levodopa. As the disease progresses, patients frequently develop dyskinesia and motor fluctuations, which are sometimes resistant to pharmacological therapy. In recent years, abnormalities in gut microbiota have been identified in these patients with a possible role in motor manifestations. Dysbiosis may reduce levodopa absorption leading to delayed “On” or “no-On” states. Among 84 consecutive patients with PD, we selected 14 with levodopa-induced dyskinesia and motor fluctuations with a Movement Disorders Society U...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
In conclusion, patients over 90 years of age had an overall low prevalence of fractures and relative preservation of bone health, suggesting a preserved bone molecular profile in these individuals. Epigenetic factors and activity levels might also have favorably affected bone health. The low percentage of osteoporosis and fractures likely reduced the morbidity and mortality in this population, potentially contributing to their overall longevity. Building a Therapy for Aging Based on SIRT6 Upregulation https://www.fightaging.org/archives/2021/08/building-a-therapy-for-aging-based-on-sirt6-upregulation/ Ge...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Eur J Pharmacol. 2021 Sep 1;910:174452. doi: 10.1016/j.ejphar.2021.174452. Online ahead of print.ABSTRACTDyskinesia and psychosis are complications encountered in advanced Parkinson's disease (PD) following long-term therapy with L-3,4-dihydroxyphenylalanine (L-DOPA). Disturbances in the glutamatergic system have been associated with both dyskinesia and psychosis, making glutamatergic modulation a potential therapeutic approach for these. Treatments thus far have sought to dampen glutamatergic transmission, for example through blockade of N-methyl-D-aspartate (NMDA) receptors or modulation of metabotropic glutamate recepto...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research
ConclusionWe did not find sufficient evidence that PD is an independent risk factor for severe COVID-19 and death. Larger studies with controls are required to understand this further. Longitudinal follow-up of these participants will allow for observation of possible long-term effects of COVID-19 in PD patients.
Source: Journal of Neurology - Category: Neurology Source Type: research
In this study, LID model rats were prepared by administrating levodopa to unilaterally 6-OHDA-lesioned rats. We analyzed changes in serotonergic neurotransmission of LID model rats to elucidate the relationship between LID and the serotonergic system and pathomechanism of the anti-dyskinetic effects of ZNS. Abnormal involuntary movements (AIMs) were most severe in intermittently levodopa-treated rats but milder in rats intermittently medicated with levodopa and ZNS. Continuously levodopa-infused rats or intermittently ZNS-injected rats did not develop AIMs, and no differences in the expression of brain-derived neurotrophic...
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Source Type: research
Neurobiol Dis. 2021 Aug 6:105473. doi: 10.1016/j.nbd.2021.105473. Online ahead of print.ABSTRACTCalDAG-GEFI (CDGI) is a protein highly enriched in the striatum, particularly in principle spiny projection neurons (SPNs). CDGI is strongly down-regulated in two hyperkinetic conditions related to striatal dysfunction: Huntington's disease and levodopa-induced dyskinesia in Parkinson's disease. We demonstrate that genetic deletion of CDGI in mice disrupts dendritic, but not somatic, M1 muscarinic receptors (M1Rs) signaling in indirect pathway SPNs. Loss of CDGI reduced temporal integration of excitatory postsynaptic potentials ...
Source: Neurobiology of Disease - Category: Neurology Authors: Source Type: research
AbstractObjectiveTo summarize the reliable risk factors of impulsive-compulsive behaviors (ICBs) in Parkinson ’s disease (PD) patients through a meta-analysis on studies in which PD-ICBs were diagnosed by clinical interview.MethodsPubMed, Embase, Web of Science, CNKI and Wanfang databases were searched. We selected studies ensuring that diagnosis of ICBs in PD patients depends on semi-structured interviews according to the clinical diagnostic criteria of ICBs. The Newcastle –Ottawa Scale was used to evaluate quality of the included studies. The analyzed factors included demographic information, clinical charact...
Source: Journal of Neurology - Category: Neurology Source Type: research
ConclusionsOur meta-analysis implicates the AA genotype of theCOMT rs4680 polymorphism as potentially increasing the risk of LID in a recessive genetic model for PD patients. Furthermore, the AG genotype of theMAO-B rs1799836 polymorphism may influence the prevalence of LID in PD patients in the heterozygote model. However, further well-designed studies with larger PD patient cohorts are required to validate these results after adjusting for confounding factors.
Source: Neurological Sciences - Category: Neurology Source Type: research
Neuropsychopharmacol Hung. 2021 Jun 1;23(2):272-280.ABSTRACTDopamine D3 receptors belong to the dopamine D2-like receptor family, which also includes D2 and D4 receptors. These receptors have limited anatomical distribution and are mainly expressed in brain regions and pathways that typically mediate the actions of antipsychotic drugs and medication used against Parkinson's disease (PD). The development of cariprazine, the fi rst D2/D3 partial agonist with prominent affi nity and preferential activity at D3 receptors over other dopamine receptor subtypes was a landmark that provided new insights into the neurochemical and ...
Source: Neuropsychopharmacologia Hungarica - Category: Psychiatry Authors: Source Type: research
More News: Brain | Dyskinesia | High Intensity Focused Ultrasound Therapy | Israel Health | Japan Health | Marketing | Medical Devices | Middle East Health | MRI Scan | Neurology | Neurosurgery | Parkinson's Disease | Ultrasound